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OBJECTIVES We sought to identify the risk factors predicting the development of dilated cardiomyopathy
(DCM) in patients with isolated congenital complete atrioventricular block (CCAVB).
BACKGROUND Recently evidence has emerged that a subset of patients with CCAVB develop DCM.
METHODS This was a retrospective study of 149 patients with CCAVB who had heart size and left
ventricular (LV) function assessed by echocardiography and chest radiography over a
follow-up period of 10 6 7 years.
RESULTS Nine patients developed DCM at the age of 6.5 6 5 years. No definite cause could be
identified. In these nine patients, CCAVB was diagnosed in eight at 23 6 2.3 weeks gestation
and in one at birth. Maternal SSA/SSB antibodies were confirmed in seven of the nine
patients. Pacemakers were implanted in eight patients in the first month and in one patient
at five years of age. The initial left ventricular end-diastolic dimension (LVEDD) was in the
96th 6 2.6 percentile and the cardiothoracic (CT) ratio was 64 6 3.8% in the nine patients
who developed DCM, and differed significantly in patients with CCAVB (p , 0.005) who
did not develop DCM. The LVEDD and CT ratio did not decrease in the patients with
CCAVB and DCM, but decreased significantly in the patients with CCAVB without DCM
(p , 0.001) once pacing was initiated. Two patients with DCM died within two months of
diagnosis; one patient is neurologically compromised; two patients received a heart transplant;
and four patients are listed for heart transplantation.
CONCLUSIONS Isolated CCAVB is associated with a long-term risk for the development of DCM. Risk
factors may be SSA/SSB antibodies, increased heart size at initial evaluation and the absence
of pacemaker-associated improvement. (J Am Coll Cardiol 2001;37:1129–34) © 2001 by the
American College of Cardiology
The prognosis for children with congenital complete atrio-
ventricular block (CCAVB) has been considered relatively
benign, with a normal life-expectancy, although the major-
ity of patients eventually require pacemaker implantation
(1). However, evidence has recently emerged that a subset of
these patients develop dilated cardiomyopathy (DCM) de-
spite early pacemaker implantation (2). Most reported
patients were diagnosed in utero to have CCAVB associated
with maternal autoantibodies directed against SSA/Ro and
SSB/La ribonucleoproteins (3). The SSA/Ro and SSB/La
antibody-induced injury to the fetal conducting system of
the heart can cause isolated CCAVB. This manifestation is
well-described (4), but associated DCM is less well studied
(2).
The purposes of this retrospective study were to investi-
gate the prognostic signs in isolated CCAVB and to identify
risk factors that may predict the development of DCM in a
subgroup of these patients. We studied all children diag-
nosed with isolated CCAVB in the participating medical
centers since 1972, focusing on patients who received a
pacemaker and patients who subsequently developed DCM
in the follow-up period.
METHODS
Study group. The study group comprised all children with
CCAVB in the absence of associated structural heart
disease, diagnosed since 1972 at the Pediatric Heart Center
of the Wilhelmina Children’s Hospital/University Medical
Center, Utrecht; University Medical Center St. Radboud,
Nijmegen; the Amsterdam Medical Center, Amsterdam,
the Netherlands; the Johns Hopkins Hospital, Baltimore;
Yale New Haven Hospital, New Haven; and the Children’s
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Hospital of Philadelphia. Echocardiograms during preg-
nancy and/or additional electrocardiographic recordings
during infancy confirmed complete and permanent atrio-
ventricular (AV) block. A total of 149 patients with isolated
CCAVB were studied after echocardiographic confirmation
of normal cardiac anatomy. Pacemakers were implanted in
111 patients during follow-up. To evaluate the effect of
pacing in patients with CCAVB, the 38 patients with
CCAVB who did not undergo pacing were excluded from
the analysis. However, none of these 38 patients developed
DCM over 7 6 6 years.
Study patients were assigned to two groups according to
whether they subsequently developed DCM (CCAVB/
DCM group) or not (CCAVB group). The CCAVB/DCM
group included nine patients who developed DCM after the
diagnosis of isolated CCAVB was made. No patient was
diagnosed with DCM at the time the CCAVB was first
diagnosed. The CCAVB group consisted of the remaining
102 patients with isolated CCAVB and a pacemaker, but
without signs or symptoms of cardiomyopathy.
Clinical data and definitions. Available demographic data
of the study cohort, including gender, age at diagnosis of
AV block, heart rate at initial cardiac evaluation and the
presence or absence of maternal autoantibodies to 48-kd
SSB/La, 52-kd SSA/Ro and 60-kd SSA/Ro ribonucleopro-
teins, were retrospectively reviewed. Information on the
presence of fetal hydrops, mode of delivery, birth weight,
gestational age at birth, heart rate and condition at birth was
also reviewed. Heart rate and age at pacemaker implantation
were documented. Abstracted data included pacemaker
mode, pacemaker complications and pacemaker re-
implantations.
All available echocardiograms performed in utero and
during the neonatal period, infancy, childhood and adoles-
cence were reviewed. Left ventricular end-diastolic dimen-
sion (LVEDD) and left ventricular end-systolic dimension
(LVESD) were measured, and p values (percentile of heart
size corrected for weight) were estimated for every LVEDD
(5) before and after the cardiomyopathy was diagnosed.
Shortening fraction (SF) was calculated as (LVEDD 2
LVESD)/LVEDD 3 100% (6). Chest radiographs were
reviewed for cardiac enlargement, pulmonary venous con-
gestion, pulmonary edema, atelectasis and/or pleural effu-
sions. Heart size was expressed as the cardiothoracic (CT)
ratio and graded for each individual patient. A CT ratio
.0.60 indicated cardiomegaly in infants #1 month of age.
In children .1 month old, a CT ratio .0.50 indicated
cardiomegaly and was categorized as mild (CT ratio 0.50 to
0.60), moderate (CT ratio of 0.60 to 0.65) or severe (CT
ratio 0.65) (7). Dilated cardiomyopathy was defined as
LVEDD in the .97th percentile with SF ,25% (8). Other
identifiable causes of ventricular dysfunction (i.e., myocar-
ditis) were not encountered.
Analysis of data. Comparisons between the CCAVB/
DCM group and the CCAVB group were performed by
using the unpaired two-sample t test or Mann-Whitney U
test for continuous data, and the chi-square test or Fisher
exact test for binary variables. Data are presented as the
mean value 6 SD. The follow-up data on heart size and
function (LVEDD, SF and CT ratio) were analyzed with
linear regression. A p value ,0.05 was considered statisti-
cally significant.
RESULTS
Clinical characteristics of study cohort. There were sig-
nificant demographic differences between the patients with
isolated CCAVB (n 5 102) and those with CCAVB who
subsequently developed DCM (n 5 9) (Table 1). The age at
diagnosis of CCAVB differed significantly between the
groups (CCAVB: 24 6 45 months; CCAVB/DCM: 23 6
1 weeks gestation; p , 0.001). The average heart rate
measured at birth was significantly lower in the patients
with CCAVB and DCM. The mean length of follow-up
was similar between the two groups (CCAVB: 10.1 6 6
years; CCAVB/DCM: 10 6 6.1 years; p . 0.10). The
SSA/Ro and SSB/La antibodies were identified in 40 (77%)
of 52 patients with CCAVB who did not develop DCM.
Laboratory studies were not performed in the remaining 50
patients with CCAVB.
Dilated cardiomyopathy was diagnosed in nine patients
(8%) at 6.5 6 5 years (median 5.7 years [range 0.4 to 16])
(Fig. 1, Table 2). Five of the nine patients with DCM were
delivered by cesarean section. Hydrops was observed in one
patient. Maternal laboratory studies confirmed SSA/Ro and
SSB/La antibodies in seven (78%) of these nine patients. In
one patient, no antibodies were identified, and in the one
remaining patient, no tests were performed. No other
features of the neonatal lupus syndrome were noted. Signs
and symptoms at the time of diagnosis of DCM included
congestive heart failure (n 5 8), increasing fatigue with
exertion (n 5 5), chest pain (n 5 2), dyspnea (n 5 4) and/or
poor feeding (n 5 2). Physical examination findings re-
vealed hepatomegaly (n 5 3), hyperactive precordium (n 5
3), crepitations (n 5 2) and/or poor perfusion of the lower
extremities (n 5 2). No patient with DCM had a history
suggestive of familial cardiomyopathy.
Echocardiograms at the time of diagnosis of DCM
revealed LVEDD measurements in the .97th percentile,
with SF of 11 6 5%. Chest radiographs at the time of
Abbreviations and Acronyms
ANT 5 adenine nucleotide translocator
AV 5 atrioventricular
CCAVB 5 congenital complete atrioventricular block
CT 5 cardiothoracic
DCM 5 dilated cardiomyopathy
LV 5 left ventricle, left ventricular
LVEDD 5 left ventricular end-diastolic dimension
LVESD 5 left ventricular end-systolic dimension
SF 5 shortening fraction
1130 Udink ten Cate et al. JACC Vol. 37, No. 4, 2001
Dilated Cardiomyopathy in Isolated CCAVB March 15, 2001:1129–34
diagnosis were available in four of nine patients and revealed
a mean CT ratio of 68 6 3.8%. Pulmonary venous conges-
tion was seen in three patients, with progression to frank
pulmonary edema in one child. Medical management in-
cluded digoxin and diuretic agents in all patients. No patient
had been treated with digoxin or diuretic agents before the
development of DCM.
Outcomes. All patients with DCM had serial echocardio-
grams and chest radiographs for 25 months of follow-up
(range 2 to 144) after the initial diagnosis. Cardiac cathe-
terization was performed in four of these nine patients at the
time of diagnosis. The mean cardiac index was 2.5 liters/
min per m2 (range 2.3 to 2.7). The pulmonary artery systolic
pressure was 27 mm Hg (range 21 to 32), and the LV
end-diastolic pressure was 15 mm Hg (range 12 to 18).
Six of these nine patients did well initially on medical
treatment, but the SF diminished with duration of
follow-up (Fig. 2). The LVEDD measurements were
$97th percentile during follow-up of the patients with
DCM. Two patients died within two months of the
diagnosis, secondary to multiorgan system failure. Two
other patients received a heart transplant three months and
7.5 years after the initial diagnosis. Four patients with
DCM are currently awaiting heart transplantation. One
patient was resuscitated shortly after the diagnosis and is
neurologically compromised.
Table 1. Study Characteristics of 111 Patients With Congenital Complete
Atrioventricular Block
Patients With
Cardiomyopathy
(Group A; n 5 9)
Control Subjects
(Group B; n 5 102)
p
Value
Gender (M/F) 7/2 45/57 NS
Age (months) at diagnosis* 3 6 1† 24 6 44† , 0.001
Prenatal 8 (89%) 27 (26%) , 0.001
At birth 1 (11%) 25 (25%) —
Postnatal 0 50 (49%) —
Heart rate at birth (beats/min) 43 6 6 62 6 14 , 0.001
Follow-up (months) 123 6 73 121 6 74 NS
Hydrops 1 (11%) 3 (3%) —
Mode of delivery (n) 8 53 —
Normal 3 (37%) 22 (42%) —
CS 5 (63%) 31 (58%) —
Gestational age
(n) 8 53 —
(weeks) 37 6 3 37 6 3 NS
Mortality 2 (22%) 1 (1%) NS
*Age of congenital complete atrioventricular block diagnosis. †Months before delivery. Data are presented as the mean value 6
SD or number (%) of patients.
CS 5 cesarean section; F 5 female; M 5 male; NS 5 not significant.
Figure 1. Kaplan-Meier curve presenting freedom from developing dilated cardiomyopathy in the years after the initial diagnosis of congenital complete
atrioventricular block.
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Pathology and etiology. Endomyocardial biopsies were
obtained in four patients with DCM (44%) and revealed no
signs of myocarditis, infection or carnitine deficiency. There
was no evidence of coronary artery abnormalities detected
by echocardiography in these nine patients. Skeletal muscle
biopsies obtained from one patient with DCM who was
SSA/Ro and SSB/La antibody-positive revealed a defi-
ciency of the adenine nucleotide translocator (ANT) (Sen-
gers’ syndrome) (9). This patient died at 10 months of age.
Pacemaker therapy. The median age at pacemaker im-
plantation of the patients with CCAVB and DCM was
significantly younger (7 days [range 1 day to 5 years]) than
that of the 102 patients with CCAVB (4 years [range 1 day
to 19 years]) (p , 0.05). The median heart rate at
pacemaker implantation in the CCAVB/DCM group was
50 beats/min (range 42 to 124), and in the CCAVB group,
55 beats/min (range 37 to 104) (p . 0.10).
The indication for pacemaker implantation in the DCM
group included: 1) heart rate ,50 beats/min (n 5 5, 56%);
2) progressive bradycardia noted on ambulatory monitoring
(n 5 1, 11%); and 3) congestive heart failure (n 5 3, 33%).
Isolated premature ventricular contractions were observed in
six patients (67%). However, no patient in the CCAVB/
DCM group had higher grade ectopy, including couplets or
salvos of ventricular tachycardia. An endocardial device was
implanted in two patients, and an epicardial system in seven
patients.
Indication for pacing in the 102 patients with CCAVB
included: 1) heart rate ,50 beats/min (n 5 48, 47%); 2)
progressive bradycardia (n 5 10, 10%); 3) syncope (n 5 11,
11%); 4) pauses .3.5 s seen on ambulatory monitoring (n 5
12, 11%); 5) exercise intolerance (n 5 10, 10%); and 6) heart
failure (n 5 11, 11%). Isolated premature ventricular con-
tractions were seen in 22 patients (21%), and ventricular
couplets in six (6%). Ventricular tachycardia was not ob-
served. Endocardial devices were initially implanted in 46
patients with CCAVB, and epicardial leads in 56 patients.
There was no significant difference in the type of pacing
employed between the two study cohorts. Dual-chamber
pacemakers were implanted in two patients with CCAVB
and DCM (22%) and in 39 patients with CCAVB (38%).
Single-ventricular chamber pacing was employed in the
Table 2. Study Characteristics of Patients With Dilated Cardiomyopathy
Patient
No.
Gender
(M/F)
Age at
Diagnosis of
DCM
HR at Birth
(beats/min)
Initial
CT Ratio
Initial
LVEDD
(%ile)
Initial
SF (%)
Indication PM
Implantation
1 M 15 yrs, 9 mos 45 63 97 35 Progressive bradycardia (A)
2 M 5 mos 50 70 97 32 HR ,50 beats/min (A)
3 F 14 yrs, 5 mos 30 71 — — HR ,50 beats/min (A)
4 M 9 mos 42 61 97 45 CHF (D)
5 M 4 yrs 2 mos 46 61 97 31 CHF (D)
6 M 2 yrs 5 mos 45 63 — — HR ,50 beats/min (A)
7 M 8 yrs — 62 97 33 CHF (A)
8 M 9 yrs, 9 mos — 65 90 29 HR ,50 beats/min (A)
9 F 5 yrs, 8 mos 45 59 97 40 CHF (A)
A 5 alive; CHF 5 congestive heart failure; CT 5 cardiothoracic; D 5 dead; DCM 5 dilated cardiomyopathy; F 5 female; HR 5 heart rate; LVEDD 5 left ventricular
end-diastolic dimension; M 5 male; PM 5 pacemaker; SF 5 shortening fracture.
Figure 2. Shortening fraction (SF) of nine patients in the first 12 months after presenting with dilated cardiomyopathy. Bold horizontal line 5 average
and range at given times.
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remaining 7 patients with CCAVB and DCM (78%) and in
63 patients with CCAVB (62%). Re-implantations were
indicated in six patients with CCAVB and DCM (67%)
and in 80 patients with CCAVB (78%, p . 0.10) due to
generator depletion or lead failure.
Echocardiographic measurements. Initial echocardio-
grams at the time of CCAVB diagnosis were obtained in 94
patients (85%) (CCAVB/DCM: n 5 7; CCAVB: n 5 87)
(Table 3). The initial LVEDD (CCAVB/DCM: 96th
percentile 6 2.6%; CCAVB: 76th percentile 6 24%; p ,
0.005), without a significant difference in LV function
(CCAVB/DCM: 36 6 5.2%; CCAVB: 39 6 7.9%; p .
0.10).
Mild mitral regurgitation was seen in four patients with
DCM and persisted on serial echocardiograms during
follow-up. Initial LVEDD values .97th percentile were
measured in 22 patients with CCAVB (21%) and showed a
decrease in LVEDD ,97th percentile within 4 6 3.5 years
after pacemaker implantation. The initial SF in these
patients was 38 6 7.1%.
Over 6.5 6 5 years, the nine patients with CCAVB who
eventually developed DCM continued to have a LVEDD
.97th percentile 6 1.8%, as well as a decrease in SF from
35.8 6 5.1% to 11 6 5%. This was significantly different
from the CCAVB cohort (n 5 102), which showed a
significant decrease in LVEDD to the 65th percentile 6
20% (p , 0.001), without a change in LV function (36 6
3.6%, p , 0.01) 7 6 6 years after pacing. A decrease in heart
size was initiated within two months (range 1 month to 1
year) after pacemaker implantation.
Radiographic features. Initial chest radiographs were
available for all nine patients who eventually developed
DCM (Table 3). There was no radiographic evidence of
pulmonary venous congestion, edema or atelectasis. All nine
patients had cardiomegaly, graded as mild (n 5 4), moder-
ate (n 5 2) or severe (n 5 3). An initial CT ratio of 64 6
3.8% was measured in the CCAVB/DCM group and
remained relatively constant over 6.5 6 5 years at 63 6
6.8%. Mild vascular congestion and perihilar edema were
observed in two patients on the initial chest radiographs and
at mid-term follow-up.
The CT ratio in the CCAVB group decreased signifi-
cantly with initiation of pacing from 57 6 7.2% to 49 6
6.3% (p , 0.01) over 7.5 6 4.6 years of follow-up. This
decrease in the CT ratio was not seen in the CCAVB/
DCM group during a similar follow-up period.
DISCUSSION
Dilated cardiomyopathy. Dilated cardiomyopathy is a
heterogeneous group of myocardial diseases characterized by
dilation and impaired systolic function of the heart (5,10).
Although specific causes can be identified, such as myocar-
ditis, familial cardiomyopathies, endocardial fibroelastosis
and metabolic disorders, most cases are idiopathic (11–13).
Similarly, no additional etiologic event could be identified in
the nine patients with isolated CCAVB who eventually
developed DCM.
SSA/Ro and SSB/La autoantibodies. The SSA/Ro and
SSB/La antibodies have been suggested to be a major
determinant (1,2) in the patients with CCAVB who even-
tually developed DCM. Evidence for a potential immuno-
pathologic role of the SSA/Ro and SSB/La antibodies in
CCAVB is described in several studies (3,4). Immunofluo-
rescent studies have shown immunoglobulin G deposition
throughout the myocardium on postmortem examination
(14,15). Taylor et al. (16) demonstrated maternal antibodies
directed against fetal cardiac tissue. Although these studies
suggest a strong relationship between SSA/Ro and SSB/La
antibodies and subsequent DCM (1,2,17), the actual mech-
anism of the disease process has not yet been documented.
The SSA/Ro and SSB/La antibody-mediated AV block was
confirmed in seven of the nine patients who developed
DCM. However, 40 of 52 tested patients with CCAVB
who did not develop DCM were also SSA/Ro- and SSB/
La-positive. Thus, antibody positivity is not predictive in
those patients with CCAVB who developed DCM.
Adenine nucleotide translocator deficiency. Although
myocardial biopsies did not provide any specific information
on DCM, skeletal muscle biopsies in one patient revealed a
deficiency of ANT, which is associated with Sengers’
syndrome (10). Sengers’ syndrome consists of a triad of
congenital cataracts, mitochondrial myopathy and hypertro-
phic cardiomyopathy and is not known to cause DCM (18).
This observation may be described as a new clinical finding
and warrants further investigation.
Pacemaker implantation. A previous study indicates that
at least 10% of SSA/Ro and SSB/La antibody-associated
patients with CCAVB do not respond favorably to pace-
maker implantation, secondary to more diffuse cardiac
involvement (2). This study observed a similar incidence (9
[8%] of 111 patients) whereby pacemaker implantation did
not decrease the LVEDD. Although cardiomegaly is a
common feature in the CCAVB population, severe dilation
of the LV is rare (8). Some reports postulate that the
increased heart size may be related to LV remodeling and
reorganization of myofibers, secondary to an increase in
Table 3 Initial Heart Size and Function in Patients With
Cardiomyopathy and Control Subjects
Patients With
Cardiomyopathy
(n 5 9)
Control
Subjects
(n 5 102)
p
Value
Echocardiographic data (n) 7 87
LVEDD (percentile) 95.8 6 2.6 75.9 6 24.3 ,0.005
SF (%) 35.8 6 5.1 40.1 6 6.2 ,0.5
Chest radiographic data (n) 9 76
CT ratio (%) 64.0 6 3.8 57.1 6 7.2 ,0.005
Normal 0 20 (26%) —
Mild 4 (44%) 40 (53%) —
Moderate 2 (22%) 11 (14%) —
Severe 3 (34%) 5 (7%) —
Data are presented as the mean value 6 SD or number (%) of patients.
Abbreviations as in Table 2.
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stroke volume and maintenance of a normal cardiac output
in the face of chronic bradycardia (19,20).
Severe LV dilation may be associated with a less effective
adaptation to this complex physiology. This study reported
that patients with CCAVB with marked LV dilation at
presentation who lack a reduction in heart size with pace-
maker implantation are at risk of developing DCM.
Pacemaker-induced DCM can be offered as a possible
etiologic factor in these patients. However, this seems
unlikely for the vast majority of the paced patients respond-
ing favorably to pacemaker support. In fact, 22 patients who
did not develop DCM and whose initial LVEDD exceeded
the 97th percentile had a reduction in LVEDD with pacing.
Etiology. In the absence of a clear etiology for the patho-
genesis of DCM in the CCAVB population, we presume
that DCM is associated with isolated CCAVB and may be
a separate preexisting condition in some patients. This
hypothesis is based on such common denominators as the
presence of SSA/SSB antibodies, lower heart rate at birth,
prenatal diagnosis of CCAVB, initial cardiac enlargement
and diminished LV shortening despite early pacemaker
implantation.
The availability of heart transplantation as a therapeutic
option has increased the importance of early and accurate
diagnosis. Two patients were successfully transplanted and
are still alive, with no recurrence of DCM. Serial echocar-
diography for evaluating LV dimensions is therefore advis-
able and may allow for early medical management (i.e.,
upgrade to a DDD pacemaker system) and listing for
potential heart transplantation.
Conclusions. Children with isolated CCAVB are at risk of
developing DCM. Risk factors may include an early in-
creased CT ratio and LV dilation, with little or no improve-
ment in ventricular size with pacing, a prenatal diagnosis of
CCAVB and a low heart rate at birth. The development of
this cardiomyopathy seems to be independent of the age of
pacemaker implantation. The relatively common occurrence
of positive maternal autoantibodies in the CCAVB group
(79%) and CCAVB/DCM group (87%) makes this an
unlikely explanation for the development of DCM. Dilated
cardiomyopathy can be considered as an associate of isolated
CCAVB in some patients. These are major issues that
should be discussed at the time of diagnosis.
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